Results of the TEXT and SOFT studies in premenopausal women with hormone receptor-positive breast cancer were presented at the ASCO plenary session. The TEXT trial enrolled 2,672 women who were assigned to receive exemestane and ovarian function suppression (OFS) for 5 years or tamoxifen and OFS following surgery; in the SOFT trial, 3,066 women were randomly assigned to the same regimens or monotherapy with tamoxifen after surgery or within 8 months of neoadjuvant or adjuvant chemotherapy. After 5 years, disease-free survival (DFS) for exemestane and OFS was 91.1%, and 87.3% for tamoxifen and OFS, showing that combining OFS with exemestane is more effective than with tamoxifen.